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1. Introduction  
The developing world, Africa included, is witnessing an alarming upsurge of cancer 
incidence. The annual number of new cancer cases is expected to double by 2020 and up to 
70% of the 20 million new cases of cancer predicted to occur yearly will be in the developing 
world (Jones et al., 1999; Ferlay et al., 2003; Yach et al., 2004). 
One startling disparity, however, between cancer in the developing and developed worlds is 
that although the overall incidence of cancer in the developing world is half of that observed 
in the developed world, survival rates in the developing world are often less than one third 
of site-specific cancers in the developed world (Sener et al., 2005). This emphasizes the 
duality of the cancer problem in Africa, for being largely a disease of modern life style, 
occurring against a background of socio-economic disparities and greater burden of 
communicable diseases.  
The study of genetic epidemiology of cancers in Africa hence entails the study of peculiar 
features of gene-environment interaction that may be largely private to Africa. In addition to 
the state of socio-economic underdevelopment that applies almost to the majority of African 
states, there is the plethora of extreme environments, wide range of climatic conditions and 
cultures, but most of all the transition state of the African communities from rural subsistent 
into urban market oriented life style. Furthermore one has to consider the notorious 
prevalence of infectious and non infectious diseases that may have a bearing both on the 
initiation of myeloid leukemia, its prognosis and management, e.g. tuberculosis (Omoti et 
al., 2009), malaria, other chronic infections, sickle cell disease (Ahmed et al., 2008) and 
common adaptive traits that could modulate the course of the disease, as well as the role of 
oncogenic viruses discussed below.  
One interesting example of a potential trade-off between malignancies and parasitic diseases 
is CD36 a multiligand receptor associated with a broad array of physiological processes, 
believed to be under selective pressure from Plasmodium falciparum, and deficient or 
polymorphic in several African populations. The role of CD36 in sickle cell crises and 
cerebral malaria is debatable. As a receptor for thrombospondin 1, CD36 plays a role in the 
regulation of angiogenesis, which may be a therapeutic strategy for controlling the 
dissemination of malignant neoplasm. Moreover, it is commonly expressed on blasts in 
acute monocytic leukemia, megakaryoblastic leukemia, and erythroleukemia (Ge and 
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Elghetany, 2005). However, CD36 negative AML cells could be found especially in those 
populations that usually do not express CD36 (like in several African populations). CD36 
negative cells appeared less susceptible to trombospondin-1 induced apoptosis, which make 
leukemic cells less vulnerable to death through this promising therapeutic strategy (Li et al., 
2003). 
On the other hand, due to the transition state, a number of risk factors believed to represent 
etiologic determinants of leukemia like use of pesticides, radiation etc. are not yet 
commonplace in Africa or at least its rural environment and may explain the differential 
distribution and the focal nature of hematological malignancies in the continent or/and 
individual countries. The potential impact of transition to a modern life style with the 
accompanying risks on the emergence and distribution of these diseases is worth our utmost 
attention. 
Cancers in their complex etiology makes an ideal arena for the classical gene versus 
environment controversy. Those who favor an upper hand for the environment had their 
views strengthened by results of studies showing that people who migrate from one country 
to another generally acquire the cancer rates of the new host country, suggesting that 
environmental or lifestyle factors rather than genetic factors are the key determinants of the 
international variation in cancer rates. As far as Africa is concerned, African Americans´ 
disease data, represent a working model to test the role of changing environment and the 
effect of life style in complex diseases. Interestingly both sides of the argument seem to find 
support. Chronic myeloid leukemia (CML) patients show worse survival for African 
American and Hispanics compared to Americans of European origin (Lee et al., 2009). 
Although the difference in ethnicity data might be argued to reflect socio-economic 
differences, the current advances in genomics enable the implication of particular genomic 
regions and genes that explain the ethnic differences in susceptibility to infectious and 
chronic diseases.  
Environmental determinants also falls short of explaining neither the “focality” of cancer 
types nor the aggressive course of some cancers in Sudan like the breast cancer, a feature 
that has been claimed to exist across Africa and even among African American women 
(reviewed by Morris and Mitchell, 2008). 
Nutritional factors have also been implicated, adding an extra layer of complexity to the 
desperately compound picture of cancer etiology. Data on nutrition is greatly deficient in 
Africa similar to other aspects of genetic epidemiology, although differences in nutritional 
practices and culture may be key in providing vital clues to the contribution of life style. A 
study in China (Zhang et al., 2008), for example, suggested that a higher intake of green tea 
is associated with a reduced risk of adult leukemia. Furthermore, a study by Ross et al. 
which involved 35.221 older women provided evidence that increased vegetable 
consumption may decrease the risk of adult leukemia (Ross et al., 2002). Moreover, AML 
risk was negatively associated with milk intake among women and tea, and positively 
associated among women with beer, wine and beef (Li et al., 2006). A prospective cohort 
study by Ma et al. (2009) showed that smoking and total meat intake were risk factors for 
AML and those who did not drink coffee appeared to have a higher risk of AML.  
Africa is still contains one of the last and few enclaves on the planet to harbor communities 
with distinctive patterns of traditional life styles that once used to characterize human 
existence. Farmers, pastoralists and hunter-gatherers- like societies do preserve their life 
style and culture and often coexist in shared terrains. These communities adopt 
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fundamentally contrasting life styles and their food cultures are different. The significance 
of such disparity to all aspects of health and disease is of interest and the study of potential 
preponderance of these community members to chronic diseases including hematological 
malignancies should be investigated. 
2. Incidence and epidemiology  
The lowest rates of leukemia reported in sub-Saharan Africa probably represent failure of 
diagnosis or reporting to some extent (Davies, 1973; Fleming, 1993 and Parkin et al., 2005). 
We should therefore use caution, when drawing conclusions based on the varying 
prevalence and incidence, as an indication of clustering of cases or an environmental or 
genetic effect, as this may simply be due to the deficiency of statistics in Africa. The 
disparity could also be a reflection of the research milieu and capacity of individual 
countries or research groups, which indeed seem to be the case as most of the current 
reports on leukemia emerges from countries with well established science capacities. 
Even with the scattered and available data, however, the difference from European and 
global trends could be observed as well as the evolution of the problem of leukemia. An 
early report from Uganda found that African children in Uganda showed a great and 
genuine deficiency of leukemia and an excess of solid lympho-reticular tumors (Davies et 
al., 1965). 
In subsequence, the situation seems to change, a study of pediatric leukemia in Cameroon, 
showed that Acute Lymphoblastic Leukemia (ALL) comprised 78.6%, while AML 21.4% of 
all pediatric acute leukemia (Obama et al., 1995). In Egypt, the lymphatic and haemopoietic 
cancer incidence in 2001 have increased approximately 11-fold compared with the incidence 
in 1972. Moreover, the incidence of leukemia among infant less than 5 years increased 
exponentially with a higher incidence among boys (Hosny et al., 2002). In Kenya, leukemia 
in children below the age of 15 years comprised 37% of leukemia in all ages. Childhood 
acute leukemia formed 52.3% of all the acute leukemia. AML and ALL occurred, in almost 
equal proportions 42 % and 46 % respectively (Kasili, 1990). In Ethiopia, a report by 
Shamebo (1990) showed that the commonest type of leukemia was CML 57.8%, acute 
leukemia and chronic lymphatic leukemia (CLL) accounted for 21.1% each. Of the acute 
leukemia, 53.3% were ALL while 46.7% were AML (Shamebo, 1990). A recent study in south 
Nigeria showed that AML comprises 12.3% and CML 23.9% of all leukemia, with a mean 
age at diagnosis of 25.6 years and 35.2 years respectively (Nwannadi et al., 2011). In the last 
25 years in Sudan CML became the predominant cancer in men, while lymphomas 
remained the second most common cancer. In women, breast, cervical and ovarian cancer 
remained the three most common cancers over both time periods, but there was also an 
increase in the incidence of CML among women (Hamad, 2006), the causes of this high 
incidence of CML are not known. 
In Europe AML presents as mainly an adult’s disease with a median age at presentation of 
64 years, accounting for around 30% of all leukemia in adults, and ~18 000 new patients are 
diagnosed in Europe each year, representing ~0.6% of all cancers. The annual incidence rate 
in Europe ranges from two per 100 000/year to four per 100 000/year. In the past decade, 
the trend in overall incidence of AML has generally been stable or slowly increasing in most 
European countries, while most cases of CML occur in adults with a median age at 
presentation around age 60. CML comprises only around 2%–3% of all the leukemia 
diagnosed in patients <20 years of age but the incidence increases with age slowly until the 
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mid-40s, then more rapidly from about one per 1000 000/year in children <10 years to two 
per 100 000 in people in the fifth decade to one per 10 000 at age 80. The disease is more 
common in males. There is no clear evidence of to geographic or ethnic background that 
predisposes to CML; however, in the United States the incidence is slightly higher in 
Caucasians than in Blacks or Hispanics (Lee et al., 2009), and it exhibits a male 
preponderance, in South African Coloured and Black people, and African Americans in 
comparison to whites but the reason for this is unexplained. (Jacobs et al., 1983). 
Furthermore, several reports showed an increased incidence of CML during the first 2 
decades of life in African subjects (Haddock , 1967; Lowe et al., 1971; Lowenthal et al., 1975), 
but other reports by Leibowitz et al., (1976) and Jacobs et al., (1983) disagree with this. 
Jacobs et al. reported that in comparison with Whites and Coloureds, however, the peak 
incidence for Blacks was lower, lying between the 3rd and 4th decades. The peak incidence 
for Coloureds was in the 4th and 5th decades, and that for Whites in the 5th and 6th (Jacobs 
et al., 1983.)  
An interesting study in United Arab Emirate (UAE) found that the rate of AML among UAE 
female nationals was higher than in nationals male and expatriates. The study proposed that 
chemicals in henna dye, which is used to decorate the body, as well as a lack of sunlight 
could be behind the increased incidence (Hassan et al., 2009). Henna is applied in many 
African countries especially Sudan where it is used by vast majority of Sudanese married 
women.  
3. Molecular etiology  
Leukemia in common with other cancers arises from mutations in a single cell, which enable 
the cell to reproduce excessively, emerging as a dominant clone. A large number of different 
mutant genes contribute to leukaemogenesis singly or, more often, in combination and 
many are leukemia sub-type specific (Greaves, 1986). The number of genetic abnormalities is 
believed to reflect the number of genes that control distinct developmental stages of blood 
formation and the multiple routes to clonal dominance. These include changes not only in 
proliferative activity, but in ability to differentiate, in resistance to cell death, in DNA repair 
activity and in general stability of the genes. Whether any particular mutant genes, or hot 
spots' for mutations within a gene, are linked to particular DNA damaging agents is a topic 
of considerable relevance to the molecular epidemiology of cancer in general. For these 
changes to happen some culprit agents has to come into action namely ionizing radiation, 
chemicals such as polycylic hydrocarbons and certain drugs, and viruses. 
The way how these extrinsic factors affect the cell genetically and epigenetically is the core 
of the functional research in cancer. Although multiple risk factors have been linked to the 
development of leukemia, however these known risk factors account for only a small 
number of observed cases. Few epidemiological studies have explored the relation between 
lifestyle, dietary factors and the incidence of adult Leukemia, and almost none has 
addressed the molecular and genetic aspects of these interactions.   
3.1 Role of viruses 
For several reasons pertaining to ecology and the human history in Africa, several 
pathogens have gained access into human genomes through the African gate. This includes 
major parasites, viral and bacterial diseases. It is not coincidence that the first well proven 
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case of viral oncogenesis that of Epstein Barr Virus (EBV) was established in Africa. EBV is a 
highly prevalent infection in the adult population in Africa and has been associated with a 
heterogeneous group of lymphomas, including Burkitt’s lymphoma (especially the endemic 
form in Africa), Hodgkin’s disease, NK, and T malignancies with cytotoxic phenotypes, and 
lymphomas in the immune-compromised patient (congenital immunodeficiency, organ 
transplantation, AIDS). (Rodriguez-Abreu et al., 2007) but not unequivocally with leukemia. 
Of the oncogenic retroviruses, the Human T-cell leukemia virus (HTLV) type-1 and type-2 
have been identified as being related to the development of rare types of leukemia and 
lymphoma. HTLV-1 is endemic in certain areas including central Africa, and is associated 
with the development of adult T-cell leukemia or lymphoma (ATLL), which accounts for 
about half of the lymphoid malignancies in the endemic areas. The virus is transmitted 
mainly from mother to child, especially by breastfeeding. Sexual transmission and blood 
transfusion are minor routes of infection and cell-free blood products are not infectious 
(Rodriguez-Abreu et al., 2007). 
The importance of oncogenic viruses stems not only from their transforming oncogenic 
properties but also from the potential methylating properties of selfish DNA.  
 Environmental determinant including infection with high-risk viruses are necessary but not 
sufficient alone in the development of cancer, as most infections regress without 
intervention. Thus, genetic host factors and cellular immune responses could be potential 
modifiers for the risk of developing cancer. In particular, p53 and Rb are considered as the 
most critical tumor suppressor genes involved in regulating cell division. The 
polymorphism on p53, which encodes either a Proline or an Arginin amino acid residue at 
codon 72, has been reported as a possible risk factor for several cancers including breast and 
cervical cancer in Sudan (Eltahir et al, submitted.).  
3.2 Population and ethnic diversity  
In the last decade the importance of ethnicity, socio-economic and gender differences in 
relation to disease incidence, diagnosis, and prognosis has been realised. Gender and ethnic 
differences in these areas should have a focus in health policy in Africa. A study by Lee et al. 
examined the demographic and clinical features of CML in an ethnically diverse population 
and found that Hispanic patients present with lower risk profile CML and achieve better 
treatment responses compared to non-Hispanic patients. The vast majority of their non-
Hispanic patients were African American or Asian. This study proposed that 
biological/genetic factor can contributes to this observed ethnic differences in disease 
presentation and behavior. Hispanic ethnic group is thought to be the least diverse ethnic 
group, at the opposite site the African descent is the most diverse ethnic group. African 
populations are characterized by greater levels of genetic diversity, extensive population 
substructure, and less linkage disequilibrium (LD) among loci compared to non-African 
populations (Reich et al., 2001; Campbell and Tishkoff, 2008). Due to the long evolutionary 
history in Africa there is more genetic diversity within and between populations in the 
African continent, than between Africans and other peoples in the world (Cavalli-Sforza, 
1997). African populations thus vary considerably in their genes. Moreover Africa shows a 
wide range of environments, climatic, vegetative and zoological. Thus human cancer patters 
are expected to show a similar degree of diversity, the study of which would contribute to 
our understanding of their causes. 
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The majority of cancers as genetic disease of complex nature involve a multiplicity of genetic 
loci that cooperates to make the disease happen (the multiple -hit theory). It is expected that 
such genetic component will be influenced by the genetic background of the population at 
risk. In one of the few studies on a cancer susceptibility genes background mutational 
profile in different populations, Africans were found to harbor more mutations in their 
BRCA2 than populations from the rest of the world (Wagner et al., 1999.) which is expected 
given their larger effective population size. 
Africans also possess a number of genetic adaptations that have evolved in response to 
diverse climates and diets, as well as exposure to infectious disease (Campbell & Tishkoff, 
2008), that diversity may carry great challenge in leukemia presentation and behavior/ 
prognosis and treatment. Moreover, experimental studies using synthetic peptides identical 
to the BCR-ABL fusion region in CML patients region have revealed the capability of 
specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, 
A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individuals 
expressing HLA-A3, B8 or DR4 have a diminished risk for the development of CML in 
Caucasian populations. A statistically significant increase in the frequency of Cw3 and Cw4 
antigens in Caucasians and European CML patients has been reported. Another report in 
Indian population showed that expression of HLA-Cw6 may result in a protective effect on 
CML acquisition (Chhaya, 2006). A study in Chinese population indicated that the 
expression of HLA-A*30, DRB1*07 might imply a protective effect on CML acquisition, 
while B*81 might be associated with CML susceptibility factors in that population (Miao et 
al., 2007). These results suggest that the development of CML is apparently associated with 
HLA phenotypes specific to each population. These data is missed in Africa and we intend 
to investigate this in Sudanese population. 
Common polymorphism like the codon 72 in p53 has been argued to unlikely have major 
genetic effect since polymorphism in loci with major deleterious nature will not be selected 
for to reach such frequencies unless it is a balanced polymorphism. (i.e. selected for under 
the influence of the other allele possessing an favorable adaptive trait). Interestingly It has 
been proposed that the p53 polymorphism at times when the risk of tumors was not a 
Human concern, gave a reproductive leverage by increasing reproductive success (Kang et 
al., 2008). The cost of such trade off will not be visible as long as the conditions that 
predispose for tumors are absent. In fact the derived allele (arginine), almost reached 
fixation in some populations. 
The p53 codon 72 was studied both in normal Sudanese (Bereir et al., 2002) and in the 
distribution of the polymorphism in different cancers in Sudan, (not including leukemia). 
The results show that the different alleles pose different risk ratios in different cancer. The 
Arg allele which is known to be more resistant to cell death was overrepresented breast 
carcinoma patients from different linguistic groups as compared to controls with an Odd 
ratio of 19.44 CI 6.6 – 78.3 P<0.0001. In cervical cancer the homozygous Arg genotype was 
detected in 42.3% (33/78) in cervical cancer patients while the heterozygous arg/pro in 
38.5% (30/78) and only 19.2% (15/78) had the pro/pro genotype, with an allele effect of 2.4 
(CI 1.12 – 5.33, P 0.015). In Burkitt´s lymphoma the opposite seems to be true with a major 
effect from the Pro allele, where the homozygous Arg accounted for only 6.9%, (OR 0.18 CI 
0.02 – 0.89, P= 0.018) while the Arg/Pro was 51.7% and pro/pro 41.4% (OR: 0.57, CI 0.23- 
1.42, P= 0.1). Possibly indicating the different biological pathways of tumorigenesis (Eltahir 
et al., submitted).  
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3.3 Gene and chromosomal rearrangements  
Cancers as a group of diseases display the entire range of inheritance modes from the single 
gene like disorder to the complex inheritance pattern seen in chronic diseases. The paucity 
of genetic investigation in Africa of cancer susceptibility genes and chromosomal 
aberrations linked to cancer, makes the picture even more opaque. The few examples 
discussed above and below demonstrate the great relevance of studying the genetic 
population structure of African populations and establishing the frequencies of the 
individual SNPs, Ins/dels and chromosomal abnormalities associated with diseases that 
may be necessary to define the molecular etiological basis of each cancer. In fact both 
molecular and genetic abnormalities became an important factor for characterising, treating 
and risk stratifying of myeloid leukemia. In 2002 the WHO classification of Myeloid 
Neoplasms showed that AML classification includes specific genetic subcategories; thus, 
determination of genetic features of the neoplastic cells must be performed if possible. Many 
recurring genetic abnormalities in the myeloid neoplasms can be identified by advanced 
molecular and cytogenetic techniques. In the WHO classification, the blast threshold for the 
diagnosis of AML is reduced from 30% to 20% blasts in the blood or marrow. In addition, 
patients with the clonal, recurring cytogenetic abnormalities t(8;21)(q22;q22), 
inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12) should be considered to have 
AML regardless of the blast percentage. On the other hand, according to the WHO 
classification, CML is defined specifically as a myeloproliferative disease that is 
characterized by the invariable presence of the Philadelphia (Ph) chromosome or the BCR-
ABL fusion gene. Although in most cases the diagnosis is easily made from morphologic 
evaluation of the blood smear, confirmation by genetic studies is essential, particularly in 
view of the advent of therapy that targets the BCR-ABL fusion protein (Vardiman et al., 
2002) 
Despite their diagnostic and prognostic values, studies on gene and chromosomal 
rearrangements associated malignancies is greatly lacking on the African continent, and in 
spite of the mandatory genotyping of the BCR-ABL as a prerequisite of administering the 
drug imatinib, in several African countries, there are very few reports on its frequencies. 
Among the few reports on its association with other leukemias, a multi-country study 
comprising 181 children with newly diagnosed ALL were tested in laboratories in India, 
Pakistan, Myanmar, and Sudan, following a common protocol. Across the four countries, 
the ETV6-RUNX1 (TEL-AML1) fusion gene was present in only 5% of cases. All the positive 
samples were from children aged 1 to 10 years, in whom the prevalence of this fusion gene, 
which is associated with good prognosis, was 7.4% (9 out of 121 samples), a much lower rate 
than reported from Western populations. In the 18 ALL cases tested in Sudan, a notable 
excess of MLL-AF4 (17%) and BCR-ABL1 (22%) fusion genes was found (Siddiqui et al., 
2010).  
The significance of studying the frequency of these rearrangements and their relation to 
pathology, is to establish the level of culpability of the molecular events. A study on 
Nigerian breast cancer patients suggest that while BRCA1 genomic rearrangement exists, it 
does not contribute significantly to BRCA1-associated risk in the Nigerian population 
(Zhang et al., 2011). 
Chromosomal translocations in myeloid leukemia yield hybrid RNAs capable of encoding 
fusion chimeric proteins. The unique amino acid sequences found in these oncogenic fusion 
proteins represent true tumor-specific antigens that are potentially immunogenic. Although 
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these leukemia-specific fusion proteins have an intracellular location, they might be 
recognized immunologically by T lymphocytes if peptides derived from the unique 
sequences are capable of presentation by the major histocompatibility complex (MHC) 
molecules on Leukemic cells (Bocchia et al., 1995). The ability of a series of synthetic peptides 
corresponding to the junctional sequences of CML-derived BCR-ABL fusion proteins 
spanning the b3a2 and b2a2 breakpoints to bind to purified class I molecules was studied by 
Bocchia et al. Four peptides derived from b3a2 CML breakpoint bound with high or 
intermediate affinity to HLA A3, A11, and B8. None of the CML b2a2 junctional peptides 
showed affinity of this magnitude for the HLA class I molecules tested. Which draw another 
important conclusion on the significance of the types of BCR-ABL fusion transcripts among 
populations in relation to vaccine development? The frequencies of the types of the fusion 
transcript in Ecuadorian population for example consist of 95% b2a2 (Paz-y-Mino et al., 
2002) indicating that they may not benefit much from such vaccine.  
 Several studies estimated the types of BCR-ABL fusion transcript in CML in different 
populations. The distribution of transcript type has been studied in European and some 
other populations (Eisenberg et al., 1988; Lee et al., 1989) with frequencies for b2a2 and b3a2 
transcripts being roughly of the order of 40% and 55%, and that for co-expression of b3a2 
and b2a2 representing 5% of the cases. A study on an Ecuadorian population, however, 
registered very different frequencies: 5% for b3a2 and 95% for b2a2 (Paz-y-Mino et al., 2002). 
In our report in Sudanese patients ( Osman et al., 2010 ), a frequency of 53.5% and 41.9% for 
b2a2 and b3a2, respectively, was reported, values that are relatively closer to those from a 
Mexican population (Arana- Trejo et al., 2002). This difference in frequencies may be due to 
the genetic differences of the populations. Many Controversial reports about the clinical 
significant of the transcript type in CML were published; however it has a considerable 
importance in the diagnosis and follow up.  
Recently, a polymorphic base in exon 13 of the BCR gene (exon b2 of the major breakpoint 
cluster region) has been identified in the eighth position before the junctional region of BCR-
ABL cDNA. Cytosine replaces thymidine; the corresponding triplets are AAT (T allele) and 
AAC (C allele), respectively, both coding for asparagine. Therefore, this polymorphism has 
no implication in the primary structure of BCR and BCR-ABL proteins. 
Co-expression of b2a2 and b3a2 transcripts has been linked to two polymorphisms, T to C at 
exon 13 and A to G at intron 13 (Meissner et al., 1998; Branford et al., 2002). However, in our 
study by Osman et al. (2010) six PCR products from four patients were sequenced to 
confirm the products of four b2a2 and two b3a2 and one was found to harbor T to C at exon 
13 and expressed only b2a2 transcript which might indicate that this exonic polymorphism 
is not obligatory for co-expression, as reported by Mondal et al. (2006). Moreover, this 
polymorphism has no implication on the primary structure of BCR and BCR-ABL proteins. 
However, since the alteration is located close to the fusion region, it may have a significant 
influence on the annealing of PCR primers, probes for real time PCR, and antisense 
oligonucleotides. This polymorphism could be also a useful marker for the differentiation of 
normal and rearranged BCR alleles in heterozygotes patients and during follow up of 
minimal residual disease. The allele frequency for this SNP varied markedly between 
different world populations, with European attaining intermediate values between African 
and Asians (Table 1)   
The molecular basis of CML is well defined and highly consistent, yet prognosis varies 
considerably. This could reflect the biological diversity occurring in normal populations. 
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Population T allele C allele 
African American 0.55 0.45 
Sub-Saharan African 0.425 0.575 
Asians 0.922 0.078 
Chinese 0.91 0.09 
Japanese 0.98 0.02 
European 0.70 0.30 
Data from NCBI/dbSNP/Short Genetic Variations  
Table 1. The frequencies of T and C alleles of BCR exon 13 SNP in different populations 
andethnic groups  
The study by Gordon et al 2003 suggest that variation among normal individuals may 
contribute to inter patient heterogeneity in CML. Differences in behaviour of haemopoietic 
progenitor cells from different normal individuals may be attributable to genetic diversity or 
other variables. de Haan et al. (2002) concluded that the expression levels of a large number 
of genes might be responsible for controlling stem cell behaviour. These collections of genes 
may be analogous to those responsible for the inter-individual diversity in progenitor cell 
behavior 
In CML, the occurrence of additional specific cytogenetic and molecular changes subsequent 
to the initiation of t(9;22) translocation herald disease progression prior to haematologic and 
clinical manifestation. These events occur in 50 to 80 percent of patients during the 
transition from the chronic phase of the disease to the accelerated and blast phases. Minor 
cytogenetic changes include monosomies of chromosomes 7, 17, and Y; trisomies of 
chromosomes 17 and 21; and translocation t(3;21)(q26;q22) (Mitelman, 1993). Major changes 
include trisomy 8, isochromosome i(17q), trisomy 19, and an extra Ph chromosome (double 
Ph). Trisomy 8 is most common, and isochromosome i(17q) occurs almost exclusively in the 
myeloid type blast phase (Kantarjian et al., 1987; Derderian et al., 1993; Mitelman, 1993). 
Molecular abnormalities may correspond to cytogenetic changes. These include 
abnormalities in p53 (on chromosome 17p13); RB1 (13q14); c-MYC (8q24); p16INK4A (9p21); 
RAS; and AML–EVI-1, a fusion protein resulting from translocation t(3;21) (q26;q22). 
Alterations of p53 (deletions, rearrangements, and mutations) occur in 20 to 30 percent of 
patients with CML in the blast phase (Ahuja et al.,1989) and are associated exclusively with 
myeloid transformation (Stuppia et al., 1997), whereas abnormalities of RB1 are associated 
more with lymphoid transformation, although the association is weaker than it was between 
p53 and myeloid transformation. Mutations of p53 in the progression of CML are associated 
with an aberrant methylation status of CML cells (Guinn et al., 1997). The introduction of a 
methyl group causing transcriptional silencing of the calcitonin gene has been found in the 
transition of chronic-phase CML to blast-phase CML (Malinen et al., 1991). Altered 
methylation was also described within the M-bcr of cells from patients with chronic-phase 
CML (Litz et al., 1996). Up to 50 percent of patients with lymphoid transformation have 
homozygous deletion of p16INK4A (Sill et al., 1995). Alterations of RB1, amplifications of c-
MYC, and mutations of RAS are less frequent (Faderl et al., 1999). 
The genetic variation in Africa is poised to constitute major challenge for diagnosis and 
management. In a world where the diagnosis and prognosis of diseases and particularly 
cancer is increasingly dependent on molecular approaches such diversity might constitute a 
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hurdle for future intervention against cancer in general. The anticancer drug imatinib has 
shown remarkable success in treatment of CML. Though a variety of resistance mechanisms 
can arise, in the majority of patients resistance coincides with reactivation of the tyrosine 
kinase activity of the BCR-ABL fusion oncoprotein. This can result from gene amplification 
and, more importantly, point mutations that disrupt the bind of imatinib to BCR-ABL itself 
(Nardi et al., 2004). Although there are no indication of resistance so far in Sudan (Alkhatib, 
2011), perhaps due to the limited use of the drug, the risk of resistance is proportional to the 
number of mutations that exist within the kinase domain and even outside the domain 
which are expected to be higher in Africa given the increased genetic diversity of African 
populations. The risk of resistance increases with the identification of Novel potential 
signaling pathways associated with drug resistance (Duy et al., 2011). 
The significance of population genetic background extends to diagnostic and prognostic 
markers that may be applied to populations and to individuals. This is expected to form a 
trend in the management of diseases of complex inheritance as we learn more of the 
biological networks in function during diseases and the role of each individual molecule. In 
a study by Elamin et al., (submitted), aimed at developing biomarkers for breast cancer, 
Peroxyredoxin V turned to be a potentially useful marker both as a prognostic and 
treatment marker in Sudanese breast cancer but not among Chinese.  
3.4 Drug metabolizing enzymes  
The drug metabolizing enzymes system has been shown to influence the susceptibility, 
sequel and outcome of cancer treatment. These systems include the Glutathione transferases 
a family member of genes encoding enzymes involved in the metabolism of many chemicals 
and shown to be polymorphic with GSTM1 and GSTT1 being deleted in proportion of 
individuals where in the homozygous state results in a phenotypic absence of the 
corresponding enzyme. These enzymes are considerably important in the detoxification of 
many environmental compounds and reactive oxygen species, and hence may constitute 
important cancer predisposition genes.  
It includes also the cytochrome P450 enzymes one of the best studied for risk association 
with cancer (Aqundez, 2004). The P450 shows conflicting and variable degree of association 
with cancer, possibly reflecting, variation in the role played by these enzymes in 
carcinogenesis and the genetic background of the population.  
 In some populations like those of the Indian subcontinent, the frequencies of homozygous 
3/3 genotype and CYP3A5*3 allele were elevated significantly in the CML group compared 
to controls (χ²=93.15, df=2, p=0.0001) (Sailaja et al., 2010).  
In India also, a statistically significant difference between an AML group and normal control 
was observed in the case of glutathione-S-transferase M1 null (odds ratio 3.25, 95% 
confidence interval 1.9-5.58, P<0.001) and N-acetyl transferase 2*6B (odds ratio 3.04, 95% 
confidence interval 1.79-5.16, P<0.001) genotypes. Combined deficiency of N-acetyl 
transferase 2 and glutathione-S-transferase M1 genes produced an odds ratio of 11.91 (95% 
confidence interval 4.06-34.96, P<0.001). Those with glutathione-S-transferase M1 null 
genotype and N-acetyl transferase 2*6B allele are at increased risk of developing AML, and 
the risk is considerably enhanced in persons with both glutathione-S-transferase M1 and N-
acetyl transferase 2 deficiency (Majumdar et al., 2008). 
Increased risk of AML has also been reported for combined polymorphisms in 
detoxification and DNA repair enzymes (Voso et al., 2007), and patients that achieved 
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complete molecular response following administration of imatinib showed significantly 
(p=0.013) higher in vivo CYP3A activity than patients achieving partial molecular response 
(Green et al., 2010). 
In Sudan impact of the distribution of the GSTM1 and GSTT1 genotype leukemic patients 
was studied in 77 leukemic patients and 107 controls by Tagelsir et al., (Submitted). The 
results suggest that these genotypes could play a role in the development of leukemia 
particularly AML. Statistical analysis showed a significant preponderance of null genotype 
of both genes among pooled cases [GSTM1 OR 3.45 (95% CI, 1.65 - 7.19); P = 0.001] for; 
GSTT1 OR 8.57 (95% CI, 3.68 -19.93); P < 0.0001]. Double null was also higher in patients 
compared to controls (P = 0.01). When the cases were stratified according to the disease 
type, AML showed the highest positive predictive value for both loci (GSTM1 P < 0.0001, 
GSTT1 P < 0.0001), ALL and CLL showed similar patterns for GSTT1 (P = 0.001) while the P-
values for GSTM1 were (0.01) and (0.007) respectively. CML displayed the least positive 
predictive value for GSTM1 (0.02), while for GSTT1 the result was as same as AML (P < 
0.0001). Double null, however, showed only association with AML (P < 0.0001). 
When the distribution of the GSTM1 and GSTT1 null genotypes were compared between 
linguistic groups of the control subjects, different percentages were obtained and GSTT1 
null genotypes was statistically different between the Afro-Asiatic and the Nilo-Saharan 
groups (P = 0.01). Difference in frequencies between Africans population is reported; 
Egyptians 15-29% (Abdel-Rahman, 1996; Hamdy et al., 2003), Tunisians 29% (Hanene et al., 
2007) and Zimbabweans 26% (Masimirembwa, et al., 1998). generally speaking the GSTM1 
frequency (10.3%) is close to sub-Saharan Africa range; Nigerians 22% (Zhao et al., 1994) and 
Zimbabweans 24% (Masimirembwa, et al., 1998). while the previously reported frequency 
from Sudan is 39% (Tiemersma et al., 2001) . Other African populations frequencies are; 
Egyptians 44-55% [Abdel-Rahman, 1996 Hamdy et al., 2003), Tunisians 50% (Hanene et al., 
2007).  
The Tagelsir study suggests an increased risk for leukemia associated with GSTM1 and 
GSTT1 null genotypes and highlights a potential role of genetic make up in leukaemogensis. 
The most statistically significant association for GSTT1 observed for both AML and CML 
may highlight a possible role of GSTT1 enzyme in protection of the myeloid series. Allelic 
variation in the gene encoding the GST isoform theta (GSTT1) enzymes was found to 
modulate the rate of benzene metabolism and excretion (Rossi et al., 1999) as well as 
benzene-induced myelotoxicity (Wan et al., 2002; Chen et al., 2007). AML – which showed 
the strongest association with both genes– comprises a distinct type of leukemia with 
different subtypes and is shown to be to somewhat associated with environmental exposure. 
Epidemiological studies have shown association between AML (M2, M4, and M5) and 
maternal exposure to marijuana and alcohol, and maternal and paternal exposures to 
pesticides, (Buckley et al., 1989; Robison et al., 1989; Severson et al., 1993; Shu et al., 1996). In 
addition to that AML is shown to be associated with exposure to benzene and may arise as 
therapy related complication after treatment of other cancers (Hoffbrand & Pettit, 2001).  
Paradoxically, the presence of these genes could not be excluded as a possible risk factor for 
leukemia as some times these enzymes are involved in bioactivation of some chemicals 
producing more reactive metabolites that could confer threat to the cell. An example of such 
risk in other cancer was found in a study on Chinese population which showed that the 
genotype combination of GSTM1 and GSTT1 double positive confers a 4.2-fold higher risk 
for developing esophageal cancer and a 2.6-fold for esophageal hyperplasia (Lin et al., 1998). 
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Fig. 1. The ladder and lever mechanism towards carcinogenesis. As the cancer cell 
struggles through multiple accumulative genetic events leading to cancer (the ladder), the 
cell will gain the upper hand in its surrounding tissue environment and eventually 
metastasize, it encounters various modifications and modulating effects that vary between 
individuals and communities. The variety of effects and the modifier action is expected to 
be greater in Africa. The up scaling of the ladder requires a lifting effect from the 
Environment (lever).  
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3.5 Epigenetics 
DNA promoter methylation and histone modification are increasingly recognized as of 
primary importance in carcinogenesis. The two forms of aberrant methylation, 
hypomethylation and hypermethylation, are both well documented features of tumor cells 
(Hanahan and Weinberg, 2000; Jones and Baylin, 2002). The transcriptional silencing of 
tumor suppressor genes via promoter CpG island hypermethylation constitutes a key 
tumorigenic process contributing to all the typical hallmarks of a cancer cell that can result 
from tumor suppressor inactivation. Profiles of tumor suppressor methylation vary 
according to tumor type (Esteller et al., 2001) and each tumor apparently displays a distinct 
‘DNA hypermethylation pattern. 
Recent studies revealed that specific patterns of DNA methylation characterize AML and 
help to distinguish AML subtypes. The contribution of this epigenetic dysregulation to 
leukemogenesis in AML is currently unclear. However, interactions between mutated 
transcription factors and epigenetic networks have already been shown to be partially 
responsible for leukemic transformation, for e.g. in acute promyelocytic leukemia (APL). 
Also, direct mutations in the epigenetic master regulators EZH2 and DNMT3A were 
recently identified in AML and in diseases leading to secondary leukemia ( Schoofs and 
Muller-Tidow, 2011).  
New studies reveal that 20% of individuals with AML harbor somatic mutations in 
DNMT3A (encoding DNA methyltransferase 3A). Although these leukemia have some gene 
expression and DNA methylation changes, a direct link between mutant DNMT3A, 
epigenetic changes and pathogenesis remains to be established. 
The disruption of key protective genes through methylation is not confined to tumor 
suppression, it extends to other vital genes in protection /susceptibility to cancer like drug 
metabolizing enzymes, as been reported for the glutathione-S-transferase P1 gene silencing 
(Karius et al., 2011)   
4. Future directions  
The burden of myeloid leukemia is expected to rise as part of a global trend of increase in 
cancer incidence. In Africa the cost of this rise given the compound problems of health 
systems will be devastating. One pressing need is to challenge the preconception of cancer 
being a disease of the developed societies and show how this image is changing under the 
rapid sweep of “globalization. Even now the limited data available on leukemia indicate 
that the incidence of CML in some African countries may exceed those of the industrialized 
world. The understanding of cancer complex etiology is a prerequisite for successful 
management and control efforts.  
Myeloid leukemia including the chronic subset that behave like a single gene disorder with 
the predominance of the Ph chromosome, posses complex etiology that includes multiple 
steps from environmental switches to inactivation of tumor suppression and other 
guardians of genome integrity and stability and ending with the impact of immune 
competence. Such complexity renders the handling of each of these potential culprits a 
daunting task especially in Africa. Without research into the etiology and genetic 
epidemiology of myeloid leukemia with all possible risk factors considered, including the 
genetic structure of population at risk, individual genetic effects, role of chronic and 
concomitant infections, and the possible trade off between infections and malignancies. For 
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diagnosis and management an integrated genomic approach is the way forward. The vision 
for this approach entails an integrated and automated approach to these analyses, bringing 
the possibility of formulating an individualized treatment plan within days of a patient's 
initial presentation. With these expectations comes the hope that such an approach will lead 
to decreased toxicities and prolonged survival for patients (Godley et al., 2011). Such 
integrated approaches are expected to meet challenges pertinent to the peculiarity of African 
genetics.  
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